BlackRock Health Sciences Opportunities Portfolio
BHSRX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Bellevue Parkway Wilmington DE United States of America 19809
- IPO Date
- Sep 9, 2011
- CIK
- 0000844779
- Website
- blackrock.com
- Similar Companies
- Business
- BlackRock Health Sciences Opportunities Portfolio (BHSRX) is an open-end mutual fund that seeks long-term growth of capital by investing at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries; these include health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. The fund concentrates more than 25% of its assets in the health sciences sector, with a portfolio comprising approximately 145 holdings, top positions in companies such as Eli Lilly and Company (8.49%), Johnson & Johnson (8.34%), Abbott Laboratories (5.26%), AbbVie Inc. (4.24%), and UnitedHealth Group Inc. (4.06%); it maintains nearly 100% allocation to health care, predominantly large-cap growth and blend stocks, with about 95% in U.S. companies and limited exposure to non-U.S. markets including the United Kingdom, Europe, and the Middle East. BHSRX, the Class R share class with a net expense ratio of 1.44%, serves institutional and restricted investors with a minimum investment of $1, operates within the Morningstar Health category, and features a portfolio turnover of 27%. Managed by BlackRock Fundamental Equities' Health Sciences team, led by Erin Xie, PhD, Managing Director and head of the team since July 31, 2003, with co-portfolio manager Xiang Liu since June 1, 2020, the fund benefits from the firm's systematic integration of environmental, social, and governance (ESG) factors, though it does not pursue a dedicated sustainable investment strategy. The broader Health Sciences Opportunities Portfolio strategy traces its origins to 1999, with the BHSRX share class launched on September 12, 2011; BlackRock, the fund's adviser and parent company, maintains its global headquarters at 50 Hudson Yards in New York, New York. In recent developments, the fund has delivered a one-year total return of -5.83% as of late 2025, underperforming its benchmark amid market volatility, while exhibiting annualized returns of 7.40% over three years, 4.50% over five years, and 8.83% over ten years; its assets under management stand at approximately $6.9 billion. No major acquisitions, partnerships, funding rounds, or structural reorganizations specific to BHSRX have been reported in the last 1-2 years, with portfolio management and strategy remaining stable under the current team amid BlackRock's broader 2025 announcements of manager changes in unrelated funds. The fund continues to emphasize opportunistic investments across global health sciences subsectors, adapting to sector dynamics such as advancements in biotechnology and pharmaceuticals.